349 related articles for article (PubMed ID: 35148401)
21. Moving towards better predictors of drug-induced Torsade de Pointes. 2-3 November 2005, Crystal City, Virginia, USA.
Cavero I; Crumb W
Expert Opin Drug Saf; 2006 Mar; 5(2):335-40. PubMed ID: 16503753
[TBL] [Abstract][Full Text] [Related]
22. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
23. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.
Salvi V; Karnad DR; Panicker GK; Kothari S
Br J Pharmacol; 2010 Jan; 159(1):34-48. PubMed ID: 19775279
[TBL] [Abstract][Full Text] [Related]
24. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.
Farkas AS; Nattel S
Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805
[TBL] [Abstract][Full Text] [Related]
25. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications.
Giorgi MA; Bolaños R; Gonzalez CD; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):54-7. PubMed ID: 20210719
[TBL] [Abstract][Full Text] [Related]
26. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
[TBL] [Abstract][Full Text] [Related]
27. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.
Darbar D; Kimbrough J; Jawaid A; McCray R; Ritchie MD; Roden DM
J Am Coll Cardiol; 2008 Feb; 51(8):836-42. PubMed ID: 18294569
[TBL] [Abstract][Full Text] [Related]
28. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
Beattie KA; Luscombe C; Williams G; Munoz-Muriedas J; Gavaghan DJ; Cui Y; Mirams GR
J Pharmacol Toxicol Methods; 2013; 68(1):88-96. PubMed ID: 23624022
[TBL] [Abstract][Full Text] [Related]
30. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Briasoulis A; Agarwal V; Pierce WJ
Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
[TBL] [Abstract][Full Text] [Related]
31. Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
Rossman EI; Wisialowski TA; Vargas HM; Valentin JP; Rolf MG; Roche BM; Riley S; Pugsley MK; Nichols J; Li D; Leishman DJ; Kleiman RB; Greiter-Wilke A; Gintant GA; Engwall MJ; Delaunois A; Authier S
J Pharmacol Toxicol Methods; 2023; 123():107270. PubMed ID: 37164235
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of drug induced QT interval prolongation.
Ponte ML; Keller GA; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
[TBL] [Abstract][Full Text] [Related]
33. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
34. Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation.
Long W; Li S; He Y; Lin J; Li M; Wen Z
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047744
[TBL] [Abstract][Full Text] [Related]
35. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
Huo J; Wei F; Cai C; Lyn-Cook B; Pang L
Toxicol Sci; 2019 Feb; 167(2):360-374. PubMed ID: 30247688
[TBL] [Abstract][Full Text] [Related]
36. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.
Polcwiartek C; Sneider B; Graff C; Taylor D; Meyer J; Kanters JK; Nielsen J
Psychopharmacology (Berl); 2015 Sep; 232(18):3297-308. PubMed ID: 26231497
[TBL] [Abstract][Full Text] [Related]
37. Prediction of Thorough QT study results using action potential simulations based on ion channel screens.
Mirams GR; Davies MR; Brough SJ; Bridgland-Taylor MH; Cui Y; Gavaghan DJ; Abi-Gerges N
J Pharmacol Toxicol Methods; 2014; 70(3):246-54. PubMed ID: 25087753
[TBL] [Abstract][Full Text] [Related]
38. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.
Hasnain M; Vieweg WV
CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced torsade de pointes: from molecular biology to bedside.
Tamargo J
Jpn J Pharmacol; 2000 May; 83(1):1-19. PubMed ID: 10887935
[TBL] [Abstract][Full Text] [Related]
40. Ciprofloxacin-induced acquired long QT syndrome.
Prabhakar M; Krahn AD
Heart Rhythm; 2004 Nov; 1(5):624-6. PubMed ID: 15851230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
